More health lost than gained from NHS spending on new medicines

News | Posted on Tuesday 17 December 2024

New medicines approved by the NHS spending watchdog NICE may have helped some patients, but their rollout has come at a heavy cost to the health of many others due to loss of funding in other areas of care, a new study reveals.

EEPRU update February 2018

Beth Woods, Senior Research Fellow at Centre for Health Economics at University of York, and one of the authors of the study, said: "This work shows that there is a need to reform pharmaceutical pricing policy in England to better serve the health needs of all patients served by the NHS.”

Read the full story on the University of York's news page